90928-92-0

Basic information

• Product Name: 3-Methyl-1,2,4- oxadiazol-5- ylMethylaMine
• Synonyms: 3-Methyl-1,2,4- oxadiazol-5- ylMethylaMine
• CAS NO: 90928-92-0
• Molecular Formula: C₄H₇N₃O
• Molecular Weight: 113.12
• Mol File: 90928-92-0.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 3-Methyl-1,2,4- oxadiazol-5- ylMethylaMine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Methyl-1,2,4- oxadiazol-5- ylMethylaMine(90928-92-0)
• EPA Substance Registry System: 3-Methyl-1,2,4- oxadiazol-5- ylMethylaMine(90928-92-0)

Safety Data

• Hazardous Substances Data: 90928-92-0(Hazardous Substances Data)

Usage

General Description

3-Methyl-1,2,4-oxadiazol-5-ylMethylaMine is a chemical compound with the molecular formula C4H7N3O. It is an organic compound that is commonly used in the synthesis of various pharmaceuticals and agrochemicals. It is a white to beige solid with a molecular weight of 113.12 g/mol. 3-Methyl-1,2,4- oxadiazol-5- ylMethylaMine is known for its diverse range of applications, including as a building block for the production of various drugs and pesticides. It is an important intermediate in the synthesis of a variety of pharmaceuticals, and it is also used in the production of agrochemicals and other organic compounds.

InChI:InChI=1S/C4H7N3O/c1-3-6-4(2-5)8-7-3/h2,5H2,1H3

Upstream product

• 253196-35-9 (N-tert-Butoxycarbonyl)-3-methyl-1,2,4-oxadiazol-5-ylmethylamine 

Downstream Products

• 1600520-78-2 C₁₅H₂₁N₅O₂ 
• 875644-71-6 5-(bromomethyl)-3-methyl-1,2,4-oxadiazole 

Relevant articles and documents

OXADIAZOLE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF

The invention provides novel beta-secretase inhibitors and methods for their including methods of treating Alzheimer's disease.

Synthesis and pharmacological profile of a series of 2,5-substituted-N,N-dimethyltryptamine derivatives as novel antagonists for the vascular 5-HT1B-like receptor

The coronary 5-HT1B-like receptor has been implicated in vasospasm and it is postulated that a 5-HT1B-like antagonist may block the detrimental action of 5-HT whilst not interfering with normal blood vessel function. The synthesis and pharmacological profile of a novel series of 2-(N-heteroaryl)carboxamido-5-substituted-N,N-dimethyltryptamine derivatives as silent (as judged by the inability of angiotensin II to unmask 5-HT1B-like receptor mediated agonist activity in the rabbit femoral artery), competitive and selective 5-HT1B-like receptor antagonists is described. Modifications to the 2-carboxamido sidechain as well as the 5-ethylene linked heterocycle are explored. N-Furfuryl-5-[2-(N-phthalimido)ethyl]-3-[2-(dimethylamino)ethyl]-1H-indole-2- carboxamide (34) was discovered which fulfilled our in vitro selection criteria and which had a favourable pharmacokinetic profile. Compound 34 showed good affinity (pKB = 7.38) for the vascular 5-HT1B-like receptor and greater than 125 fold selectivity over α1-adrenoceptor affinity. The selectivity of 34 and related compounds for the 5-HT1B-like receptor over other receptor subtypes is discussed and a mode of binding for this class of compound to a pharmacophore model is proposed. The Royal Society of Chemistry 1999.